HSBC Holdings’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12M | Buy |
69,682
+7,598
| +12% | +$1.41M | 0.01% | 883 |
|
|
2025
Q4 | $12.4M | Sell |
62,084
-20,876
| -25% | -$3.79M | 0.01% | 886 |
|
|
2025
Q3 | $12.9M | Buy |
82,960
+6,474
| +8% | +$1.03M | 0.01% | 845 |
|
|
2025
Q2 | $11.6M | Sell |
76,486
-5,327
| -7% | -$710K | 0.01% | 861 |
|
|
2025
Q1 | $12.3M | Buy |
81,813
+1,611
| +2% | +$270K | 0.01% | 831 |
|
|
2024
Q4 | $14.8M | Sell |
80,202
-1,692
| -2% | -$326K | 0.01% | 806 |
|
|
2024
Q3 | $16.1M | Sell |
81,894
-16,581
| -17% | -$3.45M | 0.01% | 791 |
|
|
2024
Q2 | $20.4M | Buy |
98,475
+21,221
| +27% | +$4.81M | 0.01% | 673 |
|
|
2024
Q1 | $20.9M | Buy |
77,254
+21,179
| +38% | +$5.06M | 0.01% | 692 |
|
|
2023
Q4 | $13.3M | Sell |
56,075
-7,068
| -11% | -$1.39M | 0.01% | 791 |
|
|
2023
Q3 | $12.4M | Buy |
63,143
+9,102
| +17% | +$1.87M | 0.01% | 765 |
|
|
2023
Q2 | $11.4M | Buy |
54,041
+10,813
| +25% | +$2.15M | 0.01% | 780 |
|
|
2023
Q1 | $8.72M | Sell |
43,228
-9,093
| -17% | -$2.06M | 0.01% | 904 |
|
|
2022
Q4 | $11.4M | Buy |
52,321
+15,755
| +43% | +$3.44M | 0.01% | 887 |
|
|
2022
Q3 | $7.11M | Buy |
36,566
+213
| +0.6% | +$46K | 0.01% | 1040 |
|
|
2022
Q2 | $7.91M | Sell |
36,353
-9,072
| -20% | -$2.22M | 0.01% | 1010 |
|
|
2022
Q1 | $13.1M | Buy |
45,425
+1,463
| +3% | +$451K | 0.02% | 769 |
|
|
2021
Q4 | $16.6M | Buy |
43,962
+4,617
| +12% | +$1.79M | 0.02% | 738 |
|
|
2021
Q3 | $16.5M | Buy |
39,345
+7,563
| +24% | +$3.14M | 0.02% | 687 |
|
|
2021
Q2 | $11.8M | Buy |
31,782
+25,615
| +415% | +$8.55M | 0.01% | 801 |
|
|
2021
Q1 | $1.8M | Sell |
6,167
-1,392
| -18% | -$387K | ﹤0.01% | 1341 |
|
|
2020
Q4 | $1.88M | Buy |
7,559
+4,811
| +175% | +$1.15M | ﹤0.01% | 1356 |
|
|
2020
Q3 | $622K | Buy |
2,748
+1,155
| +73% | +$240K | ﹤0.01% | 1800 |
|
|
2020
Q2 | $278K | Sell |
1,593
-397
| -20% | -$63.4K | ﹤0.01% | 2173 |
|
|
2020
Q1 | $255K | Sell |
1,990
-5,292
| -73% | -$794K | ﹤0.01% | 2151 |
|
|
2019
Q4 | $1.12M | Sell |
7,282
-767
| -10% | -$106K | ﹤0.01% | 1779 |
|
|
2019
Q3 | $1.07M | Sell |
8,049
-30,316
| -79% | -$4.06M | ﹤0.01% | 1911 |
|
|
2019
Q2 | $5.44M | Buy |
38,365
+32,702
| +577% | +$4.44M | 0.01% | 1113 |
|
|
2019
Q1 | $822K | Sell |
5,663
-6,508
| -53% | -$855K | ﹤0.01% | 1914 |
|
|
2018
Q4 | $1.38M | Buy |
12,171
+8,170
| +204% | +$1.02M | ﹤0.01% | 1640 |
|
|
2018
Q3 | $538K | Sell |
4,001
-41,736
| -91% | -$5.15M | ﹤0.01% | 1996 |
|
|
2018
Q2 | $5.13M | Buy |
45,737
+17,178
| +60% | +$1.86M | 0.01% | 1112 |
|
|
2018
Q1 | $3.05M | Buy |
28,559
+24,883
| +677% | +$2.68M | ﹤0.01% | 1287 |
|
|
2017
Q4 | $403K | Buy |
3,676
+684
| +23% | +$74.4K | ﹤0.01% | 1586 |
|
|
2017
Q3 | $323K | Buy |
2,992
+584
| +24% | +$60K | ﹤0.01% | 1909 |
|
|
2017
Q2 | $244K | Sell |
2,408
-882
| -27% | -$81.2K | ﹤0.01% | 1967 |
|
|
2017
Q1 | $296K | Hold |
3,290
| – | – | ﹤0.01% | 1810 |
|
|
2016
Q4 | $251K | Buy |
3,290
+280
| +9% | +$21.3K | ﹤0.01% | 2372 |
|
|
2016
Q3 | $251K | Sell |
3,010
-652
| -18% | -$54.7K | ﹤0.01% | 1826 |
|
|
2016
Q2 | $302K | Buy |
3,662
+62
| +2% | +$5.11K | ﹤0.01% | 1763 |
|
|
2016
Q1 | $274K | Sell |
3,600
-6
| -0.2% | -$444 | ﹤0.01% | 1791 |
|
|
2015
Q4 | $290K | Sell |
3,606
-602
| -14% | -$43.4K | ﹤0.01% | 1899 |
|
|
2015
Q3 | $267K | Buy |
4,208
+1,897
| +82% | +$136K | ﹤0.01% | 1672 |
|
|
2015
Q2 | $163K | Sell |
2,311
-2,374
| -51% | -$176K | ﹤0.01% | 1866 |
|
|
2015
Q1 | $371K | Buy |
+4,685
| New | +$346K | ﹤0.01% | 1660 |
|
Other funds holding CRL
VCM
VPM
HSBC Holdings's CRL Position: Q1 2026 in Review
HSBC Holdings increased its Charles River Laboratories (CRL) stake by 12% in Q1 2026, buying an estimated $1.41M and bringing the position to 69,682 shares worth $12M. The position accounts for 0.01% of the portfolio, ranked #883.
HSBC Holdings first reported a position in CRL in Q1 2015 and has held it in 45 quarters since. The position peaked at $20.9M in Q1 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- HSBC Holdings held 69,682 shares of Charles River Laboratories worth $12M as of Q1 2026.
- HSBC Holdings bought 7,598 Charles River Laboratories shares in Q1 2026, an estimated $1.41M.
- Charles River Laboratories made up 0.01% of HSBC Holdings's portfolio in Q1 2026, its #883 holding.
- HSBC Holdings first reported a position in Charles River Laboratories in Q1 2015 and has held it in 45 quarters since.
- HSBC Holdings's Charles River Laboratories position peaked at $20.9M in Q1 2024.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.